Detailed Narrative
Q3 FY25 Performance and Segment Shift
Anupam Rasayan reported a strong Q3 FY25 with consolidated operating revenue of INR 390 crores, marking a 32% YoY increase. EBITDA, including other income, grew 48% YoY to INR 121 crores, with margins expanding by 389 basis points to 31%. Profit after tax more than doubled to INR 54 crores. This growth was primarily driven by the Pharma and Polymer segments, which contributed 23% and 10% of sales respectively in 9M FY25, indicating a strategic shift from the historically dominant agrochemical sector.
9M FY25 Challenges and Agrochemical Headwinds
Despite the robust Q3, the 9M FY25 consolidated operating revenue declined 13% YoY to INR 938 crores, and EBITDA fell 14% YoY to INR 262 crores. This underperformance was attributed to a weak demand situation in the agrochemical sector, particularly in Europe, and the company's decision to withdraw business from a large Indian MNC that historically contributed approximately 15% of its total revenues. Management expects agrochemical demand to improve in Q4 FY25 and FY26.
Strategic Diversification and New Market Expansion
The company is actively diversifying its geographical and product portfolio. New contracts and LOIs with a U.S. MNC are expected to contribute over 15% of sales from the US market within the next 12-18 months. Japan is also projected to become a significant market, contributing approximately one-third of Anupam's sales over the next 2-3 years. This diversification aims to create a more balanced portfolio and reduce reliance on any single sector or geography.
Capex Completion and Green Energy Initiatives
Anupam Rasayan completed INR 650 crores of its planned INR 670 crores capex by December 31, 2024, with all new plants slated for commercialization by March 31, 2025. A new 9.2-megawatt hybrid power plant, commissioned in October 2024, is expected to generate annual energy cost savings of INR 15 crores. Combined with previous investments, 65% of the company's electricity needs will be met through green energy, demonstrating a commitment to cost optimization and sustainability.
Order Book and R&D Pipeline for Future Growth
The company's order book stands at approximately INR 10,700 crores, spread over an average of 5 to 6 years. Of this, INR 3,100 crores worth of orders have already been commercialized, with the majority of the remainder expected to commercialize in FY26. The R&D pipeline is robust, with over 65 molecules in pharma and polymer segments currently in R&D and pilot stages, poised to drive future growth.
Working Capital and Debt Management
Gross debt marginally decreased from INR 1,270 crores as of September 30, 2024, to INR 1,200 crores by December 31, 2024, primarily due to capex and term loan repayments. An additional INR 270 crores from warrants issued to promoters is expected in Q1 FY26, which will further reduce debt. Management aims to improve working capital days to a target of 180-200 days, expecting liquidation of expanded inventory as sales volumes pick up.